Merck & Co., Inc.

In its 13F for Q1 2026 (holdings as of March 31, 2026, filed May 13, 2026), Merck & Co., Inc. reported 14 stock positions worth $349.4 million. Its top holding was Moderna (MRNA) at 33.6% of the portfolio, followed by Personalis (PSNL, 25.6%) and Kymera Therapeutics (KYMR, 18.4%). Compared with Q4 2025, it opened 2 new positions and added to 1. The biggest buy was a new position in Eikon Therapeutics (EIKN).

Most Recent 13F
Q2 2026
Location
RAHWAY, NJ
CIK
0000310158
Portfolio Value
$349.4M (Q1 2026)
SEC Filing
0000310158-26-000141 ↗ filed May 13, 2026

Holdings Value

0$200.0M$400.0M$600.0M Q4 2024: $258.0M Q4 2024 Q1 2025: $164.3M Q1 2025 Q2 2025: $215.6M Q2 2025 Q3 2025: $228.0M Q3 2025 Q4 2025: $276.3M Q4 2025 Q1 2026: $349.4M $349.4M Q1 2026 Q2 2026: $526.4M Q2 2026

Holdings 14 stocks · $349.4M
MRNA Moderna Inc. 33.56% 2,308,190 $117.3M No change
PSNL Personalis Inc. 25.60% 14,044,943 $89.5M No change
KYMR Kymera Therapeutics Inc. 18.40% 772,165 $64.3M No change
ENTRADA THERAPEUTICS INC 6.28% 1,739,768 $22.0M No change
EIKN Eikon Therapeutics Inc. 5.05% 1,666,666 $17.6M New
AKTS Aktis Oncology Inc. 4.88% 952,844 $17.0M New
ALEC Alector Inc. 2.18% 3,545,719 $7.6M No change
STRO Sutro Biopharma Inc. Com SHS 1.94% 272,351 $6.8M No change
EVAX Evaxion Biotech A/S 1.29% 1,214,126 $4.5M No change
VRDN Viridian Therapeutics Inc. 0.52% 93,414 $1.8M No change
XLO Xilio Therapeutics Inc. 0.26% 105,982 $891K No change
CARM Carisma Therapeutics Inc. 0.01% 1,473,240 $48K No change
NEUP Neuphoria Therapeutics Inc. 0.01% 10,027 $41K No change
HURA Tuhura Biosciences Inc. 0.01% 19,445 $35K Add +39.4%

Portfolio Sells Q4 2025 → Q1 2026
None this quarter.

Portfolio Buys Q4 2025 → Q1 2026
EIKN Eikon Therapeutics Inc. New 5.05% +5.05
AKTS Aktis Oncology Inc. New 4.88% +4.88
HURA Tuhura Biosciences Inc. Add +39.4% 0.01% +0.01

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q2 2026 13$526.4MPSNL, MRNA, KYMR, AKTS, EIKN
Q1 2026 14$349.4MMRNA, PSNL, KYMR, ENTRADA THERAPEUTICS INC, EIKN
Q4 2025 12$276.3MPSNL, MRNA, KYMR, ENTRADA THERAPEUTICS INC, EVAX
Q3 2025 13$228.0MPSNL, MRNA, KYMR, ALEC, ENTRADA THERAPEUTICS INC
Q2 2025 13$215.6MPSNL, MRNA, KYMR, ENTRADA THERAPEUTICS INC, ALEC
Q1 2025 12$164.3MMRNA, PSNL, KYMR, ENTRADA THERAPEUTICS INC, ALEC
Q4 2024 13$258.0MMRNA, PSNL, KYMR, ENTRADA THERAPEUTICS INC, ALEC